Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database

• Автори: Rachel Prevost (Автор), Basile Chretien (Автор), Elise-Marie Minoc (Автор), Charles Dolladille (Автор), Angélique Da-Silva (Автор), Ahmad Nehme (Автор), Florence Joly (Автор), Véronique Lelong-Boulouard (Автор), Etienne Bastien (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Importance: Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s.Objective: To evaluate whether ET and iCDK4/6s are assoc...